ClinicalTrials.gg
RecruitingNCT06417008Updated Aug 1, 2025

A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer

A Phase 2/3 interventional study of HS-20117 and Aumolertinib in Non-Squamous Non-Small Cell Lung Cancer, sponsored by Hansoh BioMedical R&D Company. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-08-01.

Sponsored by Hansoh BioMedical R&D Company (part of Hansoh Pharmaceutical Group Company Limited) · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started May 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
1,080
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies in Carcinoma, Non-Small-Cell Lung by Hansoh Pharmaceutical Group Company Limited — 20 open to participants now, 22 under way, 8 of them phase 3. Carcinoma, Non-Small-Cell Lung · Hansoh Pharmaceutical Group Company Limited.

Planned enrollment
Largest of 26
1,080 · median 272
Started
2024
with 4 others
Phase 2/3
Only one
of the 26
Primary completion
2026-06
later than 12 of 21 live
Registered
13th of 26
by date

Among the 26 studies in Carcinoma, Non-Small-Cell Lung by Hansoh Pharmaceutical Group Company Limited, this one has the largest planned enrollment, is one of 5 that started in 2024, is the only one in phase 2/3, reaches primary completion later than 12 of the 21 other live ones, and was the 13th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

20 of the 26 studies in Carcinoma, Non-Small-Cell Lung by Hansoh Pharmaceutical Group Company Limited are open now, in 4 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 20 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Carcinoma, Non-Small-Cell Lung by Hansoh Pharmaceutical Group Company Limited, or all of them as a file.
02

Study summary

HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody. The purpose of this study is to assess the safety, efficacy, pharmacokinetics and immunogenicity of HS-20117 combined with Aumolertinib in participants with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions [Exon 19del] or Exon 21 L858R substitution) positive, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).

Read the detailed description

This is a multicenter Phase Ib/III clinical study evaluating the safety, efficacy, pharmacokinetics (PK), and immunogenicity of HS-20117 in combination with aumolertinib in subjects with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC). The study is divided into two phases, Phase Ib, a dose expansion study and Phase III, a confirmatory study. In the dose expansion phase (Phase Ib), HS-20117 will first be studied in combination with the standard dose of aumolertinib, to assess the efficacy, safety, tolerability, PK profile, and immunogenicity of HS-20117 in combination with aumolertinib in the target population, as well as to determine the recommended Phase III dose (RP3D). Following confirmation of the safety and efficacy of HS-20117 in combination with aumolertinib and RP3D in Phase Ib, a randomized, active-controlled, open-label, multicenter Phase III study will be initiated to assess the efficacy and safety of HS-20117 in combination with aumolertinib versus aumolertinib in the target population in the confirmatory study phase.

03

Conditions studied

  • Non-Squamous Non-Small Cell Lung Cancer

Keywords

  • Non-Small Cell Lung Cancer
  • HS-20117
  • Epidermal Growth Factor Receptor
  • c-Mesenchymal-Epithelial Transition
  • Bispecific Antibody
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females aged 18 - 75 years (inclusive).
  • Participants with newly diagnosed or cytologically confirmed, locally advanced or EGFR-sensitive mutated NSCLC (stage IIIB/IIIC/IV) that is treatment naive and not amenable to curative therapy including surgical resection or chemoradiation.
  • Agree to provide fresh or .
  • At least one target lesion per the v1.1.
  • performance status of 0-1.
  • Minimum > 12 weeks.
  • Males or Females should be using adequate measures throughout the study.
  • Females must not be pregnant at screening or have evidence of non-.
  • Have signed Form.

Exclusion criteria

Exclusion Criteria:

  • Received or are receiving the following treatments:

    1. Previous or current treatment with MET targeted therapy or EGFR targeted antibodies or antibody-drug conjugates (ADC).
    2. Traditional Chinese medicine indicated for tumors, major surgery or other local therapy within to the first dose of study drug.
    3. Presence of pleural effusion/ascites requiring clinical intervention; presence of pericardial effusion.
    4. Other non-anti-tumor drugs, strong inhibitors, strong inducers, drugs that are sensitive substrates of BCRP or P-gp, or drugs that prolong the within the washout period.
  • Presence of Grade ≥ 2 toxicities due to prior anti-tumor therapy.
  • History of other primary .
  • Untreated, or active central nervous system .
  • Inadequate bone marrow reserve or organ functions.
  • Severe, uncontrolled or active cardiovascular disorders.
  • Severe or uncontrolled systemic diseases.
  • Severe bleeding symptoms or bleeding tendencies.
  • Severe arteriovenous thrombosis occurred.
  • Serious or active infection.
  • Active infectious diseases.
  • Interstitial lung disease (ILD).
  • Serious neurological or mental disorders.
  • History of to any component of HS-20117 and Aumolertinib or their similar drugs.
  • Female subjects who are pregnant, lactating, or planning to become pregnant or breastfeed during the study period or within 6 months after the last dose of the study drug.
  • Subjects with a history of severe allergic reactions or those who have experienced severe infusion reactions
  • Participants with any condition that compromises the safety of the participant or interferes with the assessment of the study, as judged by the investigator.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,080 participants (estimated)

Study arms

  • Experimental
    Phase Ib: HS-20117 and Aumolertinib

    Participants will receive IV infusion of HS-20117 once during cycle 1 and once every 2 weeks during subsequent cycles (The duration of each treatment cycle is 28 days) at exploratory doses. Aumolertinib will be administered 110 mg orally once daily.

    Drug: HS-20117 · Drug: Aumolertinib

  • Experimental
    Phase III: HS-20117 and Aumolertinib

    Participants will receive IV infusion of HS-20117 once during cycle 1 and once every 2 weeks during subsequent cycles (The duration of each treatment cycle is 28 days) at exploratory doses. Aumolertinib will be administered 110 mg orally once daily.

    Drug: HS-20117 · Drug: Aumolertinib

  • Active comparator
    Phase III: Aumolertinib

    Participants will receive Aumolertinib 110 mg orally once daily.

    Drug: Aumolertinib

Interventions

  • Participants will receive HS-20117 once during cycle 1 and once every 2 weeks during subsequent cycles (The duration of each treatment cycle is 28 days)

    Also known as: PM1080

  • 110 mg orally once daily.

    Also known as: Almonertinib Mesilate Tablets, HS-10296, Almonertinib

06

What researchers measure

Primary outcomes

  1. [Phase Ib] Objective response rate (ORR) According to response evaluation criteria in solid tumors (RECIST) v1.1 by Investigators (INVs)

    ORR is defined as the percentage of participants with DOR of confirmed CR or confirmed PR per RECIST v1.1

    Time frame: From the date of first dose until the date of disease progression or withdrawal from study, up to approximately 40 months

  2. [Phase III] Progression-Free Survival (PFS) According to RECIST v1.1 by Independent Review Committee(IRC)

    PFS is defined as the time from randomization until the date of objective disease progression or death, whichever occurred first, based on IRC using RECIST v1.1

    Time frame: Up to approximately 40 months

Secondary outcomes

  1. [Phase Ib and III] Overall Survival (OS)

    Overall Survival is defined as the time from the date of randomization to the date of participant's death due to any cause.

    Time frame: Approximately 60 months

  2. [Phase Ib and III] Disease control rate (DCR) According to RECIST v1.1 by INVs

    DCR is defined as the percentage of patients who have a best overall response (confirmed CR, PR, or stable disease for at least 6 weeks) based on Investigator's assessment per RECIST v1.1.

    Time frame: From the date of first dose until the date of disease progression or withdrawal from study, approximately 40 months.

  3. [Phase Ib and III] Duration of response (DoR) According to RECIST v1.1 by INVs

    DoR only applies to participants whose best overall response is CR or PR based on Investigator's assessment per RECIST v1.1. The start date is the date of first documented response of CR or PR (i.e. the start date of observed response, not the date when response was confirmed), and the end date is defined as the date of the first documented progression or death due to underlying disease.

    Time frame: From the date of CR, PR until the date of disease progression or death, approximately 40 months.

  4. [Phase Ib and III] Progression-Free Survival (PFS) According to RECIST v1.1 by INVs

    PFS is defined as the time from randomization until the date of objective disease progression or death, whichever occurred first, based on IRC using RECIST v1.1

    Time frame: Up to approximately 40 months

  5. [Phase III] ORR According to RECIST v1.1 by INVs

    ORR is defined as the percentage of participants with BOR of CR or PR per RECIST v1.1

    Time frame: From the date of first dose until the date of disease progression or withdrawal from study, up to approximately 40 months

  6. [Phase III] ORR According to RECIST v1.1 by IRC

    ORR is defined as the percentage of participants with BOR of CR or PR per RECIST v1.1

    Time frame: From the date of first dose until the date of disease progression or withdrawal from study, up to approximately 40 months

  7. [Phase III] DCR According to RECIST v1.1 by IRC

    DCR is defined as the percentage of patients who have a best overall response (confirmed CR, PR, or stable disease for at least 6 weeks)

    Time frame: From the date of first dose until the date of disease progression or withdrawal from study, approximately 40 months.

  8. [Phase III] DoR According to RECIST v1.1 by IRC

    DoR only applies to participants whose best overall response is CR or PR. The start date is the date of first documented response of CR or PR (i.e. the start date of observed response, not the date when response was confirmed), and the end date is defined as the date of the first documented progression or death due to underlying disease.

    Time frame: From the date of CR, PR until the date of disease progression or death, approximately 40 months.

  9. [Phase Ib and III] Incidence and severity of treatment-emergent adverse events

    Adverse event (assessed according to NCI CTCAE v5.0) is defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.

    Time frame: From the date of first dose until 90 days after the final dose. A cycle is 28 days.

  10. [Phase Ib and III] Immunogenicity of HS-20117

    Immunogenicity will be measured by the number of participants that are ADA positive.

    Time frame: Cycle 1 Day 1: predose through EOT or follow up period (90 days after the last dose).

  11. [Phase Ib] PK parameters: Maximum serum concentration (Cmax) of HS-20117

    The Cmax is the maximum observed serum concentration of HS-20117

    Time frame: From the date of first dose until 30 days after the final dose. A cycle is 28 days.

  12. [Phase Ib] PK parameters: Trough serum concentration (Ctrough) of HS-20117

    Ctrough is the observed serum concentration immediately prior to the next administration

    Time frame: From the date of first dose until 30 days after the final dose. A cycle is 28 days.

  13. [Phase Ib] PK parameters: Area under the curve from time Zero to end of dosing interval (AUCtau) of HS-20117

    The AUCtau is defined as the area under the serum concentration-time curve during a dose interval time period(tau)

    Time frame: From the date of first dose until 30 days after the final dose. A cycle is 28 days

  14. [Phase Ib] PK parameters: Time to reach maximum observed serum concentration (Tmax) of HS-20117

    The Tmax is defined as time to reach maximum observed serum concentration of HS-20117

    Time frame: From the date of first dose until 30 days after the final dose. A cycle is 28 days.

  15. [Phase Ib] PK parameters: Terminal elimination half-life (t1/2) of HS-20117

    The t1/2 is defined as the time it takes for the concentration levels to fall to 50% of their value.

    Time frame: From the date of first dose until 30 days after the final dose. A cycle is 28 days.

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Jun 2026, 24 months after the start.

Of 56 phase 2/3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 40. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2024
First posted
May 16, 2024
StartActual
May 28, 2024
Primary completionEst.
Jun 1, 2026
CompletionEst.
Jun 1, 2030
Last update
Aug 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06417008
Responsible party
Sponsor
First posted
May 16, 2024
Start date
May 28, 2024
Primary completion
Jun 1, 2026 (estimated)
Completion
Jun 1, 2030 (estimated)
Last update
Aug 1, 2025

Study contacts

Jialei Fu
Contact
fujl@hspharm.com
+86 18652105685
Dingzhi Huang, M.D.
principal investigator · Tianjin Medical University Cancer Institute and Hospital
Yun Fan, M.D.
principal investigator · Zhejiang Cancer Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HS-20117

Start the discussion